Advertisement
AMGN vs BIIB
Which Stock Would AI Choose? Amgen (AMGN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- Amgen (AMGN) delivered Q1 2026 revenue of $8.6 billion (+6% year-over-year) with non-GAAP EPS of $5.15 (+5%), prompting raised full-year guidance of $37.1–$38.5 billion in revenue.
- Biogen (BIIB) shares have shown stronger one-year total return of 49.01% compared to Amgen (AMGN)’s 27.63%, though both outperformed the S&P 500 year-to-date.
- Amgen (AMGN) benefits from a broader product portfolio with multiple double-digit growth drivers, including Repatha (evolocumab) sales up 34% in Q1.
- Biogen (BIIB) faces upcoming Q2 2026 earnings on July 29 and has seen recent analyst target increases amid sector rotation in biotechnology.
- Relative performance in recent weeks reflects Amgen (AMGN)’s steadier fundamentals versus Biogen (BIIB)’s higher volatility and momentum-driven moves.
- Sector exposure for both centers on biotechnology, with Amgen (AMGN) emphasizing diversified therapies and Biogen (BIIB) more concentrated in neuroscience and rare diseases.
Introduction
Amgen (AMGN) and Biogen (BIIB) represent two established biotechnology companies whose stocks frequently attract attention from institutional and retail investors seeking exposure to innovative therapies. This comparison examines their recent stock behavior, business profiles, and relative positioning within the healthcare sector. Traders and long-term investors monitoring biotechnology equities, earnings momentum, and pipeline developments may find the analysis useful for assessing risk-adjusted opportunities. The review draws on observable market data and company disclosures to highlight contrasts in scale, growth drivers, and sentiment without offering forward-looking recommendations.
AMGN Overview and Recent Performance
Amgen (AMGN) develops and commercializes therapies across oncology, cardiovascular disease, inflammation, and rare conditions. In recent market activity, the stock has traded near $368, delivering a year-to-date return of 14.06% that outpaced the S&P 500. First-quarter 2026 results showed total revenue of $8.6 billion and raised full-year guidance, supported by volume growth in key products such as Repatha. Recent weeks have featured analyst rating upgrades alongside isolated mentions of product recalls, contributing to generally constructive sentiment. The company’s diversified revenue base and operating margins have helped support relative stability amid broader market fluctuations.
BIIB Overview and Recent Performance
Biogen (BIIB) focuses primarily on neuroscience, including treatments for multiple sclerosis and emerging programs in Alzheimer’s and rare neuromuscular diseases. The stock closed at $200.36 on July 8, 2026, with a year-to-date return of 13.85%. One-year performance reached 49.01%, exceeding Amgen (AMGN)’s return over the same period. Recent weeks have included analyst price-target increases and commentary on chart patterns, while the company prepares to report second-quarter results on July 29. Sentiment has reflected both pipeline interest and typical biotechnology volatility tied to clinical and regulatory updates.
Trending AI Robots
Tickeron maintains a curated section called Trending AI Robots that highlights select AI trading bots from its broader library of hundreds of bots covering thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in the trending section. Available bots span diverse trading styles, timeframes, performance statistics, and ticker sets, allowing users to review metrics such as win rates, drawdowns, and trade frequency before any engagement. This resource provides transparent data on bot characteristics without constituting investment advice.
Head-to-Head Comparison
Amgen (AMGN) operates with a larger, more diversified product portfolio that spans multiple therapeutic areas, while Biogen (BIIB) maintains a narrower focus that can amplify both upside and downside from individual assets. Recent momentum has favored Amgen (AMGN)’s steadier revenue trajectory and raised guidance, whereas Biogen (BIIB) has recorded stronger trailing twelve-month returns amid sector rotation. Risk factors include Amgen (AMGN)’s exposure to patent dynamics and manufacturing issues, contrasted with Biogen (BIIB)’s concentration in high-uncertainty clinical readouts. Both companies share biotechnology sector exposure, yet Amgen (AMGN) offers broader market positioning and Biogen (BIIB) presents greater sensitivity to neuroscience catalysts. Market sentiment currently reflects balanced analyst interest, with neither stock showing uniform dominance across metrics.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning, Tickeron’s AI models may currently assign a modest edge to Amgen (AMGN) over Biogen (BIIB). The assessment rests on Amgen (AMGN)’s diversified growth profile and recent guidance raises, which have supported more consistent performance patterns in recent market activity. Biogen (BIIB)’s higher historical volatility and upcoming earnings event introduce greater uncertainty. This probabilistic evaluation reflects data patterns rather than definitive predictions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileBIIB’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BIIB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BIIB’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- BIIB’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а -2.88% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +0.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.57%. For the same industry, the average monthly price growth was +11.20%, and the average quarterly price growth was +6.94%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
BIIB is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.57% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | BIIB | AMGN / BIIB | |
| Capitalization | 195B | 30.9B | 631% |
| EBITDA | 16.7B | 2.7B | 619% |
| Gain YTD | 11.725 | 18.774 | 62% |
| P/E Ratio | 25.08 | 22.48 | 112% |
| Revenue | 37.2B | 9.94B | 374% |
| Total Cash | 12B | 4.28B | 280% |
| Total Debt | 57.3B | 6.56B | 873% |
AMGN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 21 | 100 | |
SMR RATING 1..100 | 12 | 79 | |
PRICE GROWTH RATING 1..100 | 27 | 22 | |
P/E GROWTH RATING 1..100 | 58 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (9) in the Biotechnology industry is significantly better than the same rating for BIIB (87). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's Profit vs Risk Rating (21) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for BIIB (79). This means that AMGN’s stock grew significantly faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (22) in the Biotechnology industry is in the same range as AMGN (27). This means that BIIB’s stock grew similarly to AMGN’s over the last 12 months.
BIIB's P/E Growth Rating (14) in the Biotechnology industry is somewhat better than the same rating for AMGN (58). This means that BIIB’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 64% | 4 days ago 69% |
| Stochastic ODDS (%) | 4 days ago 47% | 4 days ago 54% |
| Momentum ODDS (%) | 4 days ago 58% | 4 days ago 74% |
| MACD ODDS (%) | 4 days ago 65% | 4 days ago 59% |
| TrendWeek ODDS (%) | 4 days ago 53% | 4 days ago 72% |
| TrendMonth ODDS (%) | 4 days ago 58% | 4 days ago 60% |
| Advances ODDS (%) | 18 days ago 57% | 18 days ago 57% |
| Declines ODDS (%) | 4 days ago 52% | 5 days ago 70% |
| BollingerBands ODDS (%) | 4 days ago 50% | 4 days ago 68% |
| Aroon ODDS (%) | 4 days ago 53% | 4 days ago 56% |
Advertisement
AMGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with BIIB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.81% | ||
| BIIB - AMGN | 62% Loosely correlated | +4.96% | ||
| PFE - AMGN | 53% Loosely correlated | +1.28% | ||
| GILD - AMGN | 52% Loosely correlated | +1.21% | ||
| SNY - AMGN | 39% Loosely correlated | +1.15% | ||
| OGN - AMGN | 22% Poorly correlated | -0.15% | ||
More | ||||
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +4.96% | ||
| PFE - BIIB | 51% Loosely correlated | +1.28% | ||
| AMGN - BIIB | 50% Loosely correlated | -0.81% | ||
| AZN - BIIB | 49% Loosely correlated | -1.25% | ||
| GILD - BIIB | 30% Poorly correlated | +1.21% | ||
| SNY - BIIB | 27% Poorly correlated | +1.15% | ||
More | ||||